<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphar.2016.00346</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Corrigendum: Discoidin Domain Receptors: Potential Actors and Targets in Cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Rammal</surname> <given-names>Hassan</given-names></name><uri xlink:href="http://loop.frontiersin.org/people/212277/overview"/></contrib>
<contrib contrib-type="author"><name><surname>Saby</surname> <given-names>Charles</given-names></name><uri xlink:href="http://loop.frontiersin.org/people/295519/overview"/></contrib>
<contrib contrib-type="author"><name><surname>Magnien</surname> <given-names>Kevin</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Van-Gulick</surname> <given-names>Laurence</given-names></name><uri xlink:href="http://loop.frontiersin.org/people/326960/overview"/></contrib>
<contrib contrib-type="author"><name><surname>Garnotel</surname> <given-names>Roselyne</given-names></name><uri xlink:href="http://loop.frontiersin.org/people/295460/overview"/></contrib>
<contrib contrib-type="author"><name><surname>Buache</surname> <given-names>Emilie</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>El Btaouri</surname> <given-names>Hassan</given-names></name></contrib>
<contrib contrib-type="author"><name><surname>Jeannesson</surname> <given-names>Pierre</given-names></name><uri xlink:href="http://loop.frontiersin.org/people/296135/overview"/></contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Morjani</surname> <given-names>Hamid</given-names></name>
<xref ref-type="author-notes" rid="fn001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/109514/overview"/></contrib>
</contrib-group>
<aff><institution>Extracellular Matrix and Cellular Dynamics, Faculty of Pharmacy, MEDyC Centre National de la Recherche Scientifique UMR7369, Reims University</institution> <country>Reims, France</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and reviewed by: Julie Gavard, French Institute of Health and Medical Research, France</p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: Hamid Morjani <email>hamid.morjani&#x00040;univ-reims.fr</email></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>09</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>7</volume>
<elocation-id>346</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>05</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>09</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2016 Rammal, Saby, Magnien, Van-Gulick, Garnotel, Buache, El Btaouri, Jeannesson and Morjani.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>Rammal, Saby, Magnien, Van-Gulick, Garnotel, Buache, El Btaouri, Jeannesson and Morjani</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="Front Pharmacol" journal-id-type="nlm-ta" vol="7" page="55" xlink:href="27014069" ext-link-type="pubmed">A corrigendum on <article-title>Discoidin Domain Receptors: Potential Actors and Targets in Cancer</article-title> Rammal, H., Saby, C., Magnien, K., Van-Gulick, L., Garnotel, R., Buache, E., et al. (2016). Front. Pharmacol. 7:55. doi: <object-id>10.3389/fphar.2016.00055</object-id></related-article>
<kwd-group><kwd>discoidin domain receptors</kwd>
<kwd>tyrosine kinase</kwd>
<kwd>extracellular matrix</kwd>
<kwd>collagen</kwd>
<kwd>cell signaling</kwd>
<kwd>cancer</kwd>
<kwd>targeted therapy</kwd></kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="12"/>
<page-count count="2"/>
<word-count count="1163"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1"><title>Corrigendum</title>
<p>Following relevant reader&#x00027;s comments and Editor&#x00027;s request, my co-authors and I would like to add some references which have been unintentionally omitted in some sections of the review. We thank the readers and the Editorial Office for pointing this out and helping us to improve the manuscript.</p>
</sec>
<sec id="s2"><title>&#x0201C;Introduction section&#x0201D; (page 2)</title>
<p>After surgery, radiation therapy (RT) has long been an integral component of cancer care. It is usually employed to locally eradicate tumor cells as well as alter tumor stroma with either curative or palliative intent (Hodge et al., <xref ref-type="bibr" rid="B4">2012</xref>; Kwilas et al., <xref ref-type="bibr" rid="B6">2012</xref>).</p>
<p>Therefore, current efforts have been focusing on understanding the molecular, cellular, and systemic processes driving cancer initiation, progression, heterogeneity, and metastatic spread (Ramos and Bentires-Alj, <xref ref-type="bibr" rid="B9">2015</xref>; Semenova et al., <xref ref-type="bibr" rid="B11">2015</xref>).</p>
<p>As a major part of the tumor ECM, type I collagen exhibits high density and altered architecture in malignant cancer and is causally linked to tumor formation and metastasis (Ren et al., <xref ref-type="bibr" rid="B10">2014</xref>).</p>
<p>Until recently, these effects on tumor cells were exclusively attributed to integrins, a major class of receptors that mediate cell interactions with extracellular matrix components. The identification of the Discoidin Domain Receptor (DDR) family as collagen receptors represents a new paradigm in the regulation of collagen-cell interactions and regulation of tumor progression (Marquez and Olaso, <xref ref-type="bibr" rid="B8">2014</xref>).</p>
<p>DDR1 and DDR2 were initially discovered by homology cloning based on their catalytic kinase domains and were orphan receptors until 1997 when Shrivastava and co-workers and Vogel and co-workers, reported that different types of collagen are functional ligands for these receptors (Leitinger, <xref ref-type="bibr" rid="B7">2014</xref>).</p>
<p>In contrast with classical growth factor tyrosine kinase receptors such as the epithelial growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) which display a rapid and transient activation, DDR1 and DDR2 are unique in that they exhibit remarkably delayed and sustained receptor phosphorylation upon binding to collagen (Iwai et al., <xref ref-type="bibr" rid="B5">2013</xref>).</p>
<p>Furthermore, many classical tyrosine kinase receptors (RTKs) undergo negative regulation such as receptor/ligand internalization and subsequent degradation or dephosphorylation by phosphatases (Fu et al., <xref ref-type="bibr" rid="B3">2013</xref>).</p>
<p>In addition, they are uniquely positioned to function as sensors for ECM and to regulate a wide range of cell functions such as migration, cell proliferation, cytokine secretion, and ECM homeostasis/remodeling (Borza and Pozzi, <xref ref-type="bibr" rid="B1">2014</xref>).</p>
</sec>
<sec id="s3"><title>&#x0201C;Structure, function and regulation of DDRs&#x0201D; section (page 3)</title>
<p>DDRs control important aspects of cell behavior including proliferation, migration, adhesion, and ECM remodeling but are dysregulated in various human diseases. They are both activated by several types of collagen. However, this activation strictly requires collagen to be in its native and triple-helical conformation. Heat-denatured collagen is not recognized by DDRs (Valiathan et al., <xref ref-type="bibr" rid="B12">2012</xref>; Carafoli and Hohenester, <xref ref-type="bibr" rid="B2">2013</xref>).</p>
<p>Surprisingly, the substitution of five peripheral amino acids in DDR2 with their DDR1 counterparts converts DDR2 into a receptor of type IV collagen (Carafoli and Hohenester, <xref ref-type="bibr" rid="B2">2013</xref>).</p>
</sec>
<sec id="s4"><title>Author contributions</title>
<p>All authors contributed to the designing, writing and the validation of the last version of the manuscript.</p>
</sec>
<sec id="s5"><title>Funding</title>
<p>This work was supported by grants from Ligue Contre le Cancer 2015 (CCIR Grand-Est). CS is recipient of PhD fellowships from the French Ministry of Higher Education and Research.</p>
<sec><title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borza</surname> <given-names>C. M.</given-names></name> <name><surname>Pozzi</surname> <given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Discoidin domain receptors in disease</article-title>. <source>Matrix Biol</source>. <volume>34</volume>, <fpage>185</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.matbio.2013.12.002</pub-id><pub-id pub-id-type="pmid">24361528</pub-id></citation>
</ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carafoli</surname> <given-names>F.</given-names></name> <name><surname>Hohenester</surname> <given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>Collagen recognition and transmembrane signalling by discoidin domain receptors</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1834</volume>, <fpage>2187</fpage>&#x02013;<lpage>2194</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2012.10.014</pub-id><pub-id pub-id-type="pmid">23128141</pub-id></citation>
</ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname> <given-names>H. L.</given-names></name> <name><surname>Valiathan</surname> <given-names>R. R.</given-names></name> <name><surname>Arkwright</surname> <given-names>R.</given-names></name> <name><surname>Sohail</surname> <given-names>A.</given-names></name> <name><surname>Mihai</surname> <given-names>C.</given-names></name> <name><surname>Kumarasiri</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling</article-title>. <source>J. Biol. Chem.</source> <volume>288</volume>, <fpage>7430</fpage>&#x02013;<lpage>7437</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R112.444158</pub-id><pub-id pub-id-type="pmid">23335507</pub-id></citation>
</ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname> <given-names>J. W.</given-names></name> <name><surname>Ardiani</surname> <given-names>A.</given-names></name> <name><surname>Farsaci</surname> <given-names>B.</given-names></name> <name><surname>Kwilas</surname> <given-names>A. R.</given-names></name> <name><surname>Gameiro</surname> <given-names>S. R.</given-names></name></person-group> (<year>2012</year>). <article-title>The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors</article-title>. <source>Semin. Oncol.</source> <volume>39</volume>, <fpage>323</fpage>&#x02013;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2015.07.010</pub-id><pub-id pub-id-type="pmid">27633417</pub-id></citation>
</ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname> <given-names>L. K.</given-names></name> <name><surname>Payne</surname> <given-names>L. S.</given-names></name> <name><surname>Luczynski</surname> <given-names>M. T.</given-names></name> <name><surname>Chang</surname> <given-names>F.</given-names></name> <name><surname>Xu</surname> <given-names>H.</given-names></name> <name><surname>Clinton</surname> <given-names>R. W.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants</article-title>. <source>Biochem. J.</source> <volume>454</volume>, <fpage>501</fpage>&#x02013;<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20121750</pub-id><pub-id pub-id-type="pmid">23822953</pub-id></citation>
</ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwilas</surname> <given-names>A.R.</given-names></name> <name><surname>Donahue</surname> <given-names>R.N.</given-names></name> <name><surname>Bernstein</surname> <given-names>M.B.</given-names></name> <name><surname>Hodge</surname> <given-names>J.W.</given-names></name></person-group> (<year>2012</year>). <article-title>In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer</article-title>. <source>Front. Oncol</source>. <volume>2</volume>:<issue>104</issue>. <pub-id pub-id-type="doi">10.3389/fonc.2012.00104</pub-id><pub-id pub-id-type="pmid">22973551</pub-id></citation>
</ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leitinger</surname> <given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>Discoidin domain receptor functions in physiological and pathological conditions</article-title>. <source>Int. Rev. Cell Mol. Biol</source>. <volume>310</volume>, <fpage>39</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-800180-6.00002-5</pub-id><pub-id pub-id-type="pmid">24725424</pub-id></citation>
</ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marquez</surname> <given-names>J.</given-names></name> <name><surname>Olaso</surname> <given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>Role of discoidin domain receptor 2 in wound healing</article-title>. <source>Histol. Histopathol</source>. <volume>29</volume>, <fpage>1355</fpage>&#x02013;<lpage>1364</lpage>. <pub-id pub-id-type="doi">10.14670/HH-29.1355</pub-id><pub-id pub-id-type="pmid">24781958</pub-id></citation>
</ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname> <given-names>P.</given-names></name> <name><surname>Bentires-Alj</surname> <given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Mechanism-based cancer therapy: resistance to therapy, therapy for resistance</article-title>. <source>Oncogene</source> <volume>34</volume>, <fpage>3617</fpage>&#x02013;<lpage>3626</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2014.314</pub-id><pub-id pub-id-type="pmid">25263438</pub-id></citation>
</ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname> <given-names>T.</given-names></name> <name><surname>Zhang</surname> <given-names>W.</given-names></name> <name><surname>Liu</surname> <given-names>X.</given-names></name> <name><surname>Zhao</surname> <given-names>H.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia</article-title>. <source>J. Pathol</source>. <volume>234</volume>, <fpage>526</fpage>&#x02013;<lpage>537</lpage>. <pub-id pub-id-type="doi">10.1002/path.4415</pub-id><pub-id pub-id-type="pmid">25130389</pub-id></citation>
</ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semenova</surname> <given-names>E. A.</given-names></name> <name><surname>Nagel</surname> <given-names>R.</given-names></name> <name><surname>Berns</surname> <given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Origins, genetic landscape, and emerging therapies of small cell lung cancer</article-title>. <source>Genes Dev</source>. <volume>29</volume>, <fpage>1447</fpage>&#x02013;<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1101/gad.263145.115</pub-id><pub-id pub-id-type="pmid">26220992</pub-id></citation>
</ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valiathan</surname> <given-names>R. R.</given-names></name> <name><surname>Marco</surname> <given-names>M.</given-names></name> <name><surname>Leitinger</surname> <given-names>B.</given-names></name> <name><surname>Kleer</surname> <given-names>C. G.</given-names></name> <name><surname>Fridman</surname> <given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Discoidin domain receptor tyrosine kinases: new players in cancer progression</article-title>. <source>Cancer Metastasis Rev</source>. <volume>31</volume>, <fpage>295</fpage>&#x02013;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-012-9346-z</pub-id><pub-id pub-id-type="pmid">22366781</pub-id></citation>
</ref>
</ref-list>
</back>
</article>